Entries in Anal Cancer (2)


HPV Vaccine Protects against Anal Cancer in Women

Jeffrey Hamilton/Thinkstock(WASHINGTON) -- New research offers women one more reason to get vaccinated against the human papillomavirus (HPV).  In addition to lowering the risk of cervical, vulvar, and vaginal cancer, the vaccine also protects against anal cancer.

It is believed that about 90 percent of anal cancer is caused by an HPV infection.  Although anal cancer is rare, it has become more prevalent in recent years in the United States, nearly doubling in prevalence in the past decade.  About 5,300 people are diagnosed with anal cancer each year, the majority of whom are women, according to the American Cancer Society.

"I think we can expect to see a profound reduction in anal cancer among women vaccinated," Aimée Kreimer, the lead author on the study and investigator at the National Cancer Institute, said.

"We know that screening for cervical works because rates have been plummeting, but for anal cancer, rates are on the rise and there is no official screening process for anal cancer in women.  With the vaccine, we can have women getting vaccinated for cervical cancer who will get this added benefit of protection against anal cancer," Kreimer said.

In a study of more than 4,000 women aged 18 to 25, researchers at the National Cancer Institute and the National Institutes of Health found that the HPV vaccine was protective against anal cancer in 62 percent of women.  Among women who had no previous exposure to HPV infection, the rate of prevention was even higher at 84 percent.  Researchers followed women for four years after the first vaccination.

"This is a significant study because we are accumulating evidence that anal cancers in men and women can be prevented by HPV vaccination," Dr. Kevin Ault, associate professor of gynecology and infectious disease at Emory University School of Medicine in Atlanta, said.

Although the Food and Drug Administration approved the HPV vaccine for the prevention of anal cancer in boys and girls ages 9 to 26 in December of 2010, the focus of research at that time was in preventing anal cancer in men who have sex with men.  What's exciting about this research, said Dr. Samuel Katz, professor and chairman of the department of pediatrics at the Duke University Medical Center in Durham, North Carolina, is that now there's evidence showing that it's preventative in women as well.

Further strengthening the findings is the study's finding that the vaccine is effective even in women 18 and older.  Current recommendations suggest that girls get vaccinated as early as age 9 in order to increase the likelihood that they will be vaccinated before they become sexually active and might be exposed to HPV.

Copyright 2011 ABC News Radio


HPV Vaccine Approved for Prevention of Anal Cancer

Photo Courtesy - Getty Images(WASHINGTON) -- The FDA has approved the human papillomavirus (HPV) vaccine Gardasil, which is already approved to prevent cervical and vaginal cancer in women and genital warts in both sexes, for the prevention of anal cancer in males and females ages nine to 26, MedPage Today reports.

A randomized trial including both men and women found that Gardasil was 78 percent effective in preventing anal cancer related to HPV. 

The FDA noted that the vaccination for HPV is not an effective method of anal cancer prevention for those who already have the virus.

"Treatment for anal cancer is challenging; the use of Gardasil as a method of prevention is important as it may result in fewer diagnoses and the subsequent surgery, radiation or chemotherapy that individuals need to endure," Dr. Karen Midthun, director of the FDA's Center for Biologics Evaluation and Research, said in a statement.

MedPage also reports that 90 percent of anal cancer cases stem from HPV.  Uncommon to the general population, about 5,300 people are diagnosed in the U.S. with anal cancer each year, with more cases occurring in women than men.

Copyright 2010 ABC News Radio 

ABC News Radio